3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
102
Neoplasm Metastasis
13
Neoplasms
6
Triple Negative Breast Neoplasms
5
Breast Diseases
5
Neoplasms by Site
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Unilateral Breast Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms, Male
2
Breast Cancer Female
2
Advanced Breast Cancer
2
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Interventions
capivasertib
2
Fulvestrant
2
ribociclib
1
palbociclib
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
abemaciclib
×
Breast
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled